BCR-ABL kinase is dead; long live the CML stem cell.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease driven by the BCR-ABL fusion tyrosine kinase.
• Tyrosine kinase inhibitor (TKI) therapy achieves long-term remission but fails to eradicate CML stem cells.
• The reason for TKI resistance in CML stem cells is debated: insufficient BCR-ABL inhibition or lack of BCR-ABL dependence.

Discussion:

• This study definitively shows that BCR-ABL kinase is active within CML stem cells.
• TKIs effectively inhibit this BCR-ABL kinase activity in CML stem cells.
• Crucially, TKI treatment does not impair CML stem cell survival; instead, these cells revert to cytokine dependence.

Key Insights:

• CML stem cells are not dependent on BCR-ABL for their survival.
• BCR-ABL kinase remains active in CML stem cells despite TKI therapy.
• CML stem cells can adapt to cytokine-dependent survival mechanisms.

Outlook:

• These findings challenge the concept of BCR-ABL addiction in CML stem cells.
• Understanding stem cell behavior is crucial for developing curative CML therapies.
• Future therapeutic strategies may need to target cytokine signaling pathways or alternative dependencies.